R&D Longevity is not a consumer trend, but a pipeline strategy p... Longevity is being framed as a consumer movement when, in reality, it is a pharmaceutical pipeline challenge.
Patients Prioritising dermatology to reduce pressure on healthcare se... Chronic skin conditions, particularly CHE, remain some of the most underestimated, yet pervasive, challenges affecting people across Europe.
Patients Will at-home treatments save the global healthcare industry? With global healthcare systems failing, it’s time to make patients active participants in their own health.
News Survey reveals heavy burden of chronic hand eczema People with chronic hand eczema (CHE) have reported the serious impact the condition can have on their daily lives in a UK survey.
Healthcare The end-of-life care conundrum Research advises against aggressive cancer treatment at the end-of-life stages of the disease.
Views & Analysis Why should pharma invest in digital products for those livin... Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
